Jerusalem, Israel

Mila Gomberg

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 2004-2017

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mila Gomberg: Innovator in Pharmaceutical Formulations

Introduction

Mila Gomberg is a prominent inventor based in Jerusalem, Israel. She has made significant contributions to the field of pharmaceutical formulations, particularly in the development of sustained-release medications. With a total of 2 patents, her work focuses on improving the efficacy and delivery of important therapeutic agents.

Latest Patents

Mila's latest patents include a sustained-release donepezil formulation and venlafaxine formulations. The sustained-release donepezil formulation is designed for an acetylcholinesterase inhibitor, comprising donepezil and at least two gel-forming polymers. This innovative formulation aims to enhance the therapeutic effects of donepezil over an extended period. The venlafaxine formulations patent provides a method for treating subjects with venlafaxine, featuring a delayed burst release mechanism that allows for effective absorption primarily through the colon over a period of at least 24 hours.

Career Highlights

Throughout her career, Mila has worked with notable companies such as Dexcel Pharma Tech, Ltd and Dexcel Pharma Technologies Ltd. Her experience in these organizations has allowed her to refine her skills in pharmaceutical development and innovation.

Collaborations

Mila has collaborated with several professionals in her field, including Adel Pinhasi and Avi Avramoff. These partnerships have contributed to her success and the advancement of her inventions.

Conclusion

Mila Gomberg's contributions to pharmaceutical formulations demonstrate her commitment to innovation in medicine. Her patents reflect her expertise and dedication to improving patient care through advanced drug delivery systems.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…